ATE406371T1 - Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung - Google Patents

Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung

Info

Publication number: ATE406371T1
Authority: AT; Austria
Prior art keywords: methods; decrease; infection; treatment; active ingredients
Prior art date: 2000-11-02

Application number

AT01989211T

Other languages

English (en)

Inventor

Nigel Greig

Karen Shaw

Qiang-Sheng Yu

Harold Holloway

Tada Utsuki

Timothy Soncrant

Donald Ingram

Arnold Brossi

Anthony Giordano

Gordon Powers

Diane Davidson

Michael Sturgess

Original Assignee

Us Gov Health & Human Serv

Torreypines Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-02

Filing date

2001-11-02

Publication date

2008-09-15

2001-11-02 Application filed by Us Gov Health & Human Serv, Torreypines Therapeutics Inc filed Critical Us Gov Health & Human Serv

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE406371T1 publication Critical patent/ATE406371T1/de

Links

238000000034 method Methods 0.000 title abstract 3
101710137189 Amyloid-beta A4 protein Proteins 0.000 title 1
101710151993 Amyloid-beta precursor protein Proteins 0.000 title 1
102100022704 Amyloid-beta precursor protein Human genes 0.000 title 1
239000004480 active ingredient Substances 0.000 title 1
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
208000015181 infectious disease Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
150000004657 carbamic acid derivatives Chemical class 0.000 abstract 2
231100000331 toxic Toxicity 0.000 abstract 2
230000002588 toxic effect Effects 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/345—Nitrofurans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

AT01989211T 2000-11-02 2001-11-02 Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung ATE406371T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US24532900P	2000-11-02	2000-11-02

Publications (1)

Publication Number	Publication Date
ATE406371T1 true ATE406371T1 (de)	2008-09-15

Family

ID=22926225

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01989211T ATE406371T1 (de)	2000-11-02	2001-11-02	Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung

Country Status (7)

Country	Link
US (5)	US7153882B2 (de)
EP (1)	EP1349858B1 (de)
AT (1)	ATE406371T1 (de)
AU (2)	AU2002243323B2 (de)
CA (1)	CA2465534C (de)
DE (1)	DE60135579D1 (de)
WO (1)	WO2002048150A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002048150A2 (en) *	2000-11-02	2002-06-20	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
US20040024043A1 (en) *	2002-03-22	2004-02-05	Nigel Greig	Method for treating cognitive disorders
US9068234B2 (en)	2003-01-21	2015-06-30	Ptc Therapeutics, Inc.	Methods and agents for screening for compounds capable of modulating gene expression
US8460864B2 (en)	2003-01-21	2013-06-11	Ptc Therapeutics, Inc.	Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US8426194B2 (en)	2003-01-21	2013-04-23	Ptc Therapeutics, Inc.	Methods and agents for screening for compounds capable of modulating VEGF expression
US7521481B2 (en)	2003-02-27	2009-04-21	Mclaurin Joanne	Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004262970B2 (en) *	2003-08-07	2010-03-18	Merck Sharp & Dohme Limited	Treatment for Alzheimer's disease and related conditions
WO2005049868A1 (en) *	2003-11-17	2005-06-02	Pct Therapeutics, Inc.	Methods and agents for screening for compounds capable of modulating her2 expression
US20050182044A1 (en) *	2004-02-17	2005-08-18	Bruinsma Gosse B.	Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
GB0410238D0 (en) *	2004-05-07	2004-06-09	Merck Sharp & Dohme	Therapeutic agents
US20050272804A1 (en) *	2004-06-08	2005-12-08	Axonyx, Inc	Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor
WO2006060082A1 (en) *	2004-10-22	2006-06-08	THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH	Tricyclic compounds, preparation thereof and use thereof as cholinesterase activity inhibitors
US20060105940A1 (en) *	2004-11-03	2006-05-18	Axonyx, Inc.	Compound useful in the treatment or prevention of cognitive disorders associated with diabetes and associated methods
CA2587487A1 (en) *	2004-11-12	2006-05-18	Pfizer, Inc.	Method of measuring amyloid-beta peptides
US9095573B2 (en) *	2005-08-01	2015-08-04	University Of Central Florida Research Foundation, Inc.	Method of biasing implanted human neural stem cells away from differentiation into glial cells by (+)phenserine to modulate the concentration of soluble βAPP in tissue or CSF
US8283115B1 (en)	2007-06-20	2012-10-09	Ptc Therapeutics, Inc.	Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en)	2007-06-22	2012-10-09	Ptc Therapeutics, Inc.	Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
KR20110111403A (ko)	2009-02-05	2011-10-11	고쿠리츠 다이가쿠 호진 교토 다이가쿠	인돌린 유도체
US20100317730A1 (en) *	2009-06-12	2010-12-16	Shaya Elias K	Treatment for menopausal and perimenopausal vasomotor symptons
WO2012058031A2 (en) *	2010-10-28	2012-05-03	Qr Pharma, Inc.	Novel method for preparation of bisnorcymerine and salts thereof
US20120225922A1 (en)	2011-03-04	2012-09-06	Qr Pharma	Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
EP3334425B1 (de)	2015-08-14	2020-12-16	QR Pharma	Verfahren zur behandlung oder prävention von akuten hirn- oder nervenläsionen
US10864192B2 (en)	2016-01-15	2020-12-15	Aristea Translational Medicine Corporation	Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
US10111860B1 (en)	2016-01-15	2018-10-30	Aristea Translational Medicine Corporation	Compositions and methods for treating concussion
WO2017214197A1 (en)	2016-06-06	2017-12-14	University Of Central Florida Research Foundation, Inc.	Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions
CA3083015A1 (en)	2017-05-24	2018-11-28	Qr Pharma, Inc.	Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans
US12297244B2 (en)	2019-06-05	2025-05-13	Rensselaer Polytechnic Institute	Systems and methods for inhibiting γ-secretase production of amyloid-β peptides
EP4259157A4 (de) *	2020-12-09	2024-07-10	Caamtech, Inc.	Dialkyltryptamine und ihre therapeutischen verwendungen
WO2025017530A1 (en)	2023-07-19	2025-01-23	Assia Chemical Industries Ltd.	Solid state forms of buntanetap and process for preparation thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2890223A (en) *	1956-03-22	1959-06-09	Research Corp	1-benzyl, 2-methyl, 5-methoxy tryptamine
US4791107A (en) *	1986-07-16	1988-12-13	Hoechst-Roussel Pharmaceuticals, Inc.	Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use
US4900748A (en) *	1988-03-04	1990-02-13	The United States Of America As Represented By The Department Of Health And Human Services	Carbamates related to (-)-physostigmine as cholinergic agents
US5260452A (en) *	1989-11-03	1993-11-09	Hoechst-Roussel Pharmaceuticals Inc.	4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof
FR2674522B1 (fr)	1991-03-26	1993-07-16	Lipha	Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
DE69233255T2 (de) *	1991-09-26	2004-05-27	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Carbamatanalogen von thiaphysovenin, pharmazeutische zusammensetzungen und verfahren zur hemmung von cholinesterasen
US5171750A (en) *	1991-09-26	1992-12-15	The United States Of America As Represented By The Department Of Health And Human Services	Substituted phenserines as specific inhibitors of acetylcholinesterase
FR2707639B1 (fr)	1993-06-30	1995-10-13	Pf Medicament	Nouveaux composés indoliques dérivés d'arylamines comme ligands sélectifs des récepteurs 5HT1D et 5HT1B.
JPH07271066A (ja)	1994-03-29	1995-10-20	Mitsubishi Paper Mills Ltd	電子写真感光体
US5403851A (en) *	1994-04-05	1995-04-04	Interneuron Pharmaceuticals, Inc.	Substituted tryptamines, phenalkylamines and related compounds
WO1996003377A1 (en)	1994-07-27	1996-02-08	Sankyo Company, Limited	Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors
BR9806184A (pt)	1997-07-09	2001-06-19	Axonyx	Inibidores de butirilcolinesterase altamente seletivos para o tratamento e o diagnóstico da doença de alzheimer e demências
AU765427B2 (en)	1998-02-25	2003-09-18	Genetics Institute, Llc	Inhibitors of phospholipase enzymes
US20020004198A1 (en) *	1998-12-16	2002-01-10	Hardwicke Mary Ann	Novel anti-infectives
US20010007877A1 (en) *	1998-12-16	2001-07-12	George O. Burton	Novel anti-infectives
GB9918962D0 (en) *	1999-08-11	1999-10-13	Cerebrus Ltd	Chemical compounds xxii
WO2001034146A1 (en)	1999-11-08	2001-05-17	Smithkline Beecham Corporation	Novel anti-infectives
WO2001078721A1 (en)	2000-04-13	2001-10-25	Mayo Foundation For Medical Education And Research	Aβ42 LOWERING AGENTS
WO2002048150A2 (en) *	2000-11-02	2002-06-20	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof

2001
- 2001-11-02 WO PCT/US2001/048175 patent/WO2002048150A2/en not_active Ceased
- 2001-11-02 DE DE60135579T patent/DE60135579D1/de not_active Expired - Lifetime
- 2001-11-02 EP EP01989211A patent/EP1349858B1/de not_active Expired - Lifetime
- 2001-11-02 AU AU2002243323A patent/AU2002243323B2/en not_active Expired
- 2001-11-02 CA CA002465534A patent/CA2465534C/en not_active Expired - Lifetime
- 2001-11-02 US US10/415,765 patent/US7153882B2/en not_active Expired - Lifetime
- 2001-11-02 AT AT01989211T patent/ATE406371T1/de active
- 2001-11-02 AU AU4332302A patent/AU4332302A/xx active Pending
2006
- 2006-06-20 US US11/455,959 patent/US20060270729A1/en not_active Abandoned
2009
- 2009-01-21 US US12/357,115 patent/US7786162B2/en active Active
2010
- 2010-07-22 US US12/841,888 patent/US8258172B2/en not_active Expired - Fee Related
2012
- 2012-07-26 US US13/559,186 patent/US8691864B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20120295946A1 (en)	2012-11-22
AU4332302A (en)	2002-06-24
CA2465534A1 (en)	2002-06-20
DE60135579D1 (de)	2008-10-09
WO2002048150A2 (en)	2002-06-20
US7786162B2 (en)	2010-08-31
US20090131501A1 (en)	2009-05-21
US8258172B2 (en)	2012-09-04
CA2465534C (en)	2009-10-27
EP1349858B1 (de)	2008-08-27
US20060270729A1 (en)	2006-11-30
WO2002048150A3 (en)	2003-08-07
AU2002243323B8 (en)	2002-06-24
US7153882B2 (en)	2006-12-26
US20040138282A1 (en)	2004-07-15
EP1349858A2 (de)	2003-10-08
US8691864B2 (en)	2014-04-08
AU2002243323B2 (en)	2007-07-12
US20110021594A1 (en)	2011-01-27

Legal Events

Date

Code

Title

Description

2009-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1349858

Country of ref document: EP

Publication	Publication Date	Title
ATE406371T1 (de)	2008-09-15	Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung
EA200400482A1 (ru)	2004-12-30	Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
ATE202701T1 (de)	2001-07-15	Behandlung und prophylaxe von durch parasiten oder bakterien verursachten erkrankungen
DE60207383D1 (de)	2005-12-22	Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen
ATE487493T1 (de)	2010-11-15	Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
DE60312031D1 (de)	2007-04-05	Hydroxyethylamin-derivate für die behandlung von alzheimer
DE60319066D1 (de)	2008-03-27	1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
DE60126980D1 (de)	2007-04-12	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE60042153D1 (de)	2009-06-18	Pharmauzetisch zusammensetzung nitratenquelle und ansäuerungsmitteln enthaltende zur behandlung von offenen wunden und verbrennungen
DE69909818D1 (de)	2003-08-28	Pyrazolopyimidinon-derivate zur behandlung von impotenz
DE59911740D1 (de)	2005-04-14	Topisch anwendbare mittel gegen nagelpilzerkrankungen
ATE373474T1 (de)	2007-10-15	Substituierte 2-aminotetraline zur behandlung von depressionen
ATE201597T1 (de)	2001-06-15	Verabreichung von riluzol zur behandlung von neuro-aids
ATE318133T1 (de)	2006-03-15	Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
ATE412646T1 (de)	2008-11-15	Zur behandlung von schmerzen geeignete therapeutische mittel
ATE323084T1 (de)	2006-04-15	Für die behandlung von alzheimer krankheit geeignete makrocyclen
EA200301040A1 (ru)	2004-04-29	Способ производства фармацевтической композиции низкой дозы
DE69034226D1 (de)	2006-08-03	Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
BG108426A (bg)	2005-01-31	Нови производни на сулфоновата киселина
DE602004017871D1 (de)	2009-01-02	Zubereitungen zur behandlung von arthritischen erscheinungen
ATE349998T1 (de)	2007-01-15	Creme zur behandlung von sonnengeschädigter haut
EA200401319A1 (ru)	2005-04-28	Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
ATE40946T1 (de)	1989-03-15	Arzneimittel oder prophylaktisches mittel zur behandlung von epilepsie.
ATE205399T1 (de)	2001-09-15	Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
ATE252383T1 (de)	2003-11-15	Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen